Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
तुलना करने के लिए मीट्रिक्स | IMRX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIMRXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −6.5x | −5.1x | −0.5x | |
PEG अनुपात | −0.17 | −0.15 | 0.00 | |
क़ीमत/बुक | 1.7x | 5.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 19.5x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 158.0% | 62.1% | 50.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | −2.8% | 6.5% | अनलॉक करें |